Markets.com Logo

CELG-RI

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    0.0297$
  • Previous Close
    0.0297$
  • 52 Week Change
    0.13$
  • Day Range
    0.00$
  • 52 Week High/Low
    0.015$ - 0.1418$
  • Dividend Per Share
    --
  • Market cap
    0$
  • EPS
    --
  • Beta
    --
  • Volume
    --

About

The financial product symbol CELG-RI.US referred to rights issued by Bristol Myers Squibb (BMS) tied to the former contingent value rights (CVRs) associated with the acquisition of Celgene. The rights were intended to provide holders with potential future payments based on the FDA approvals of certain Celgene products – namely, liso-cel (JCAR017), bb2121, and fedratinib. As of November 2020, it was determined that the requirements for payment were not met, and the rights expired worthless. Therefore, CELG-RI.US no longer holds any value or represents any active financial instrument.

Gold's Safe-Haven Status Under Scrutiny: Market Dynamics and Price Outlook

Emma Rose|--

Trump's Iran War Exit Without a Deal: Reshaping Middle East Energy Security and Power Dynamics

Emma Rose|--
European market insights: What is the European stock market doing right now?

European market insights: What is the European stock market doing right now?

Ghko B|--
EUR/USD Analysis Today: EUR/USD Gains to 1.1550 as Middle East Uncertainty Lingers

EUR/USD Analysis Today: EUR/USD Gains to 1.1550 as Middle East Uncertainty Lingers

Ghko B|--

Microsoft at a Crossroads: AI Hurdles and Cloud Resilience Amidst Market Volatility

Sophia Claire|--

Iran's Hormuz Gambit: Leveraging a Chokepoint for Economic Leverage and Global Impact

Ava Grace|--

Gold Market Resilience: Navigating Sell-offs and Sustaining Bull Run

Noah Lee|--

Factors

Celgene Acquisition: CELG-RI.US represented contingent value rights (CVRs) tied to milestones in Bristol Myers Squibb's acquisition of Celgene. The success or failure of drugs like liso-cel, bb2121, and ozanimod meeting specific FDA approval and sales targets directly influenced the CVR's value.

Drug Approval Decisions: FDA decisions regarding the aforementioned drugs were critical. Positive approval boosted the likelihood of milestone payments and increased the CVR price; negative decisions significantly reduced it.

Sales Performance: Actual sales figures for approved drugs impacted whether the required sales milestones were met. Strong sales increased confidence in milestone payouts, driving up the CVR's price, while weak sales had the opposite effect.

Regulatory Environment: Changes in regulations affecting drug pricing or market access could have affected the projected revenue for the drugs tied to the CVRs, thereby influencing the CVR's value.

Market Sentiment: Overall investor sentiment towards the pharmaceutical industry and Bristol Myers Squibb influenced trading activity and demand for the CVRs.

Time to Expiration: As the deadlines for achieving milestones approached, the CVR's price became more sensitive to news and data releases, reflecting the shrinking window of opportunity for payouts.

Clinical Trial Data: New clinical trial data related to the relevant drugs could alter expectations about their future sales potential, impacting the CVR's value.

Macroeconomic Factors: Broader economic conditions, such as interest rates and inflation, could have indirectly influenced investor appetite for riskier assets like CVRs.

People Also Watch

Latest news

US Steel and Aluminum Tariffs Revamped: Simplification Amidst Potential Cost Increases

Noah Lee|--

SpaceX Files Secret IPO Bid, Eyeing Record-Breaking $1.75 Trillion Valuation

Ava Grace|--

US Intelligence: Iran Unwilling to Engage in Substantive Talks to End War

Sophia Claire|--

Latest Education Articles

What Is Sensex in Stock Market: Meaning, Calculation, and Why It Matters for Investors

What Is Sensex in Stock Market: Meaning, Calculation, and Why It Matters for Investors

Ghko B|--
Investing basics for beginners: What are the 4 economic indicators?

Investing basics for beginners: What are the 4 economic indicators?

Frances Wang|--
CFDs vs Options: What’s the Difference?

CFDs vs Options: What’s the Difference?

Julian Parker|--